Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Rating of “Buy” from Analysts

Benitec Biopharma Inc. (NASDAQ:BNTC) has received an average rating of “Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $22.60.

Several brokerages have recently commented on BNTC. Leerink Partners began coverage on Benitec Biopharma in a research note on Monday, July 22nd. They set an “outperform” rating and a $13.00 price target on the stock. Guggenheim began coverage on Benitec Biopharma in a research note on Thursday, September 12th. They set a “buy” rating and a $17.00 price target on the stock. JMP Securities boosted their price target on Benitec Biopharma from $16.00 to $18.00 and gave the stock a “market outperform” rating in a research note on Monday, October 14th. Oppenheimer assumed coverage on Benitec Biopharma in a research note on Wednesday, October 16th. They set an “outperform” rating and a $35.00 price target on the stock. Finally, Leerink Partnrs upgraded Benitec Biopharma to a “strong-buy” rating in a research report on Monday, July 22nd.

Benitec Biopharma Price Performance

Shares of NASDAQ:BNTC opened at $11.48 on Wednesday. The business’s 50 day simple moving average is $9.23 and its 200-day simple moving average is $8.42. The firm has a market capitalization of $107.54 million, a price-to-earnings ratio of -6.01 and a beta of 0.90. Benitec Biopharma has a 12 month low of $2.69 and a 12 month high of $12.89.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BNTC. Janus Henderson Group PLC raised its holdings in Benitec Biopharma by 35.5% in the 1st quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock valued at $1,266,000 after acquiring an additional 64,092 shares during the last quarter. GAMMA Investing LLC raised its holdings in Benitec Biopharma by 53.0% in the 2nd quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 1,884 shares during the last quarter. Simplify Asset Management Inc. acquired a new position in Benitec Biopharma in the 2nd quarter valued at $358,000. Finally, Nantahala Capital Management LLC acquired a new position in Benitec Biopharma in the 2nd quarter valued at $5,881,000. 52.19% of the stock is currently owned by institutional investors and hedge funds.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.